Laurus Labs is pivoting toward high-margin contract manufacturing, with its CDMO segment now contributing 41 percent of revenue. While the firm forecasts significant earnings growth, current valuations suggest a cautious approach for new capital.
Strategic Shift to CDMO
Laurus Labs has successfully pivoted its business model, reducing dependency on anti-retroviral revenue from 67 percent in fiscal year 2019 to 41 percent today. The Contract Development and Manufacturing Organisation (CDMO) division is now the firm's primary engine, boasting a 33 percent compound annual growth rate over the past six years. Notably, 41 percent of the company's first-quarter revenue for fiscal year 2027 stems from this sector, signaling a successful transition toward diversified, higher-margin operations.
Capex and Operational Scaling
The company is aggressively scaling infrastructure to support this growth, raising its capital expenditure guidance for fiscal year 2027 to Rs 2,000 crore. This investment follows a period of heavy spending, with Rs 4,300 crore deployed over the last four years. Management is betting on high-value segments, specifically in precision fermentation and complex oncology treatments. The Vizag fermentation facility is slated for completion by late 2026, which is expected to bolster the company's precision fermentation capabilities within 18 months of operational start.
Advanced Therapeutic Platforms
Laurus Labs is carving out a niche in Antibody-Drug Conjugates (ADC), developing a one-stop service platform that manages everything from payload linkers to fill-finish processes. By in-licensing clinical-stage ADC molecules from Aarvik Therapeutics, the company is accelerating its technology absorption. Furthermore, the partnership with KRKA for oncology injectables and solid oral facilities in Hyderabad remains on schedule, with operations expected to phase in throughout 2027. This infrastructure expansion underpins the company's target of a 26 percent earnings CAGR over the coming two years.
Market Valuation Concerns
Despite the robust operational outlook and improved leverage profile—with net debt to EBITDA falling to 1.3x—the stock’s current market pricing reflects these expectations. Trading at 41x EV/EBITDA for fiscal year 2028, the company leaves little room for margin error. While early shareholders may benefit from long-term compounding, prospective investors might find more attractive entry points as the firm navigates its intensive capital cycle.